Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vascular Biogenics reported $12.7M in Market Capitalization this April of 2024, considering the latest stock price and the number of outstanding shares.Data for Vascular Biogenics | VBLT - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vascular Biogenics reported $0 in Debt for its fiscal quarter ending in March of 2022. Data for Vascular Biogenics | VBLT - Debt including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vascular Biogenics reported $1M in Operating Expenses for its fiscal quarter ending in September of 2023. Data for Vascular Biogenics | VBLT - Operating Expenses including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vascular Biogenics reported $-3297000 in EBITDA for its fiscal quarter ending in March of 2023. Data for Vascular Biogenics | VBLT - Ebitda including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vascular Biogenics reported $481K in Sales Revenues for its fiscal quarter ending in September of 2022. Data for Vascular Biogenics | VBLT - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last February in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vascular Biogenics reported $20.94M in Assets for its fiscal quarter ending in September of 2023. Data for Vascular Biogenics | VBLT - Assets including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vascular Biogenics reported 7 in Employees for its fiscal year ending in December of 2022. Data for Vascular Biogenics | VBLT - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vascular Biogenics reported $63K in Interest Expense on Debt for its fiscal quarter ending in September of 2023. Data for Vascular Biogenics | VBLT - Interest Expense On Debt including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vascular Biogenics reported $-0.48 in EPS Earnings Per Share for its fiscal quarter ending in September of 2023. Data for Vascular Biogenics | VBLT - EPS Earnings Per Share including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Not seeing a result you expected?
Learn how you can add new datasets to our index.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vascular Biogenics reported $12.7M in Market Capitalization this April of 2024, considering the latest stock price and the number of outstanding shares.Data for Vascular Biogenics | VBLT - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last March in 2025.